Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2014, Article ID 964069, 10 pages
http://dx.doi.org/10.1155/2014/964069
Review Article

IL-6 as a Druggable Target in Psoriasis: Focus on Pustular Variants

1Department of Dermatology, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
2Laboratory for Investigative Dermatology, The Rockefeller University, 1230 York Avenue, New York, NY 10065, USA

Received 30 November 2013; Accepted 8 May 2014; Published 13 July 2014

Academic Editor: Clive Liu

Copyright © 2014 Andrea Saggini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. A. Lowes, T. Kikuchi, J. Fuentes-Duculan et al., “Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells,” Journal of Investigative Dermatology, vol. 128, no. 5, pp. 1207–1211, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. D. A. Martin, J. E. Towne, G. Kricorian et al., “The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings,” Journal of Investigative Dermatology, vol. 133, no. 1, pp. 17–26, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Ragaz and A. B. Ackerman, “Evolution, maturation, and regression of lesions of psoriasis. New observations and correlation of clinical and histologic findings,” The American Journal of Dermatopathology, vol. 1, no. 3, pp. 199–214, 1979. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Balato, M. Schiattarella, R. di Caprio et al., “Effects of adalimumab therapy in adult subjects with moderate-to-severe psoriasis on Th17 pathway,” Journal of the European Academy of Dermatology and Venereology, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Di Cesare, P. Di Meglio, and F. O. Nestle, “The IL-23Th17 axis in the immunopathogenesis of psoriasis,” Journal of Investigative Dermatology, vol. 129, no. 6, pp. 1339–1350, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. X. Shi, L. Jin, E. Dang et al., “IL-17A upregulates keratin 17 expression in keratinocytes through STAT1-and STAT3-dependent mechanisms,” Journal of Investigative Dermatology, vol. 131, no. 12, pp. 2401–2408, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Kagami, H. L. Rizzo, J. J. Lee, Y. Koguchi, and A. Blauvelt, “Circulating Th17, Th22, and Th1 cells are increased in psoriasis,” Journal of Investigative Dermatology, vol. 130, no. 5, pp. 1373–1383, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. N. H. Shear, J. Prinz, K. Papp, R. G. B. Langley, and W. P. Gulliver, “Targeting the interleukin-12/23 cytokine family in the treatment of psoriatic disease,” Journal of Cutaneous Medicine and Surgery, vol. 12, supplement 1, pp. S1–S10, 2008. View at Google Scholar · View at Scopus
  9. S. H. Kardaun, H. Kuiper, V. Fidler, and M. F. Jonkman, “The histopathological spectrum of acute generalized exanthematous pustulosis (AGEP) and its differentiation from generalized pustular psoriasis,” Journal of Cutaneous Pathology, vol. 37, no. 12, pp. 1220–1229, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. N. Sanchez and A. B. Ackerman, “Subcorneal pustular dermatosis: a variant of pustular psoriasis,” Acta Dermato-Venereologica, vol. 59, no. 85, pp. 147–151, 1979. View at Google Scholar · View at Scopus
  11. L. Skov, F. J. Beurskens, C. O. C. Zachariae et al., “IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis,” The Journal of Immunology, vol. 181, no. 1, pp. 669–679, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. A. B. Ackerman, “Subtle clues to diagnosis by conventional microscopy. Neutrophils within the cornified layer as clues to infection by superficial fungi,” The American Journal of Dermatopathology, vol. 1, no. 1, pp. 69–75, 1979. View at Google Scholar · View at Scopus
  13. A. Feily, M. R. Namazi, and H. Seifmanesh, “Generalized psoriasis-like dermatophytosis due to Trichophyton rubrum,” Acta Dermatovenerologica Croatica, vol. 19, no. 3, pp. 209–211, 2011. View at Google Scholar · View at Scopus
  14. A. Robinson, A. S. van Voorhees, S. Hsu et al., “Treatment of pustular psoriasis: From the medical board of the National Psoriasis Foundation,” Journal of the American Academy of Dermatology, vol. 67, no. 2, pp. 279–288, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Borges-Costa, R. Silva, L. Gonçalves, P. Filipe, L. S. De Almeida, and M. M. Gomes, “Clinical and laboratory features in acute generalized pustular psoriasis: a retrospective study of 34 patients,” American Journal of Clinical Dermatology, vol. 12, no. 4, pp. 271–276, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Ikeda, H. Takahashi, Y. Suga et al., “Therapeutic depletion of myeloid lineage leukocytes in patients with generalized pustular psoriasis indicates a major role for neutrophils in the immunopathogenesis of psoriasis,” Journal of the American Academy of Dermatology, vol. 68, no. 4, pp. 609–617, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. H. B. Naik and E. W. Cowen, “Autoinflammatory pustular neutrophilic diseases,” Dermatologic Clinics, vol. 31, no. 3, pp. 405–425, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. A. M. G. Brunasso, M. Puntoni, W. Aberer, C. Delfino, L. Fancelli, and C. Massone, “Clinical and epidemiological comparison of patients affected by palmoplantar plaque psoriasis and palmoplantar pustulosis: a case series study,” British Journal of Dermatology, vol. 168, no. 6, pp. 1243–1251, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Viguier, F. Aubin, E. Delaporte et al., “Efficacy and safety of tumor necrosis factor inhibitors in acute generalized pustular psoriasis,” Archives of Dermatology, vol. 148, no. 12, pp. 1423–1425, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. N. Smith, K. L. Harms, A. C. Hines et al., “Acute treatment of generalized pustular psoriasis of von Zumbusch with single-dose infliximab,” Journal of the American Academy of Dermatology, vol. 68, no. 6, pp. e187–e189, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. G. Egnatios, M. M. Warthan, R. Pariser, and A. F. Hood, “Pustular psoriasis following treatment of rheumatoid arthritis with TNF-alpha inhibitors,” Journal of Drugs in Dermatology, vol. 7, no. 10, pp. 975–977, 2008. View at Google Scholar · View at Scopus
  22. E. Rallis, C. Korfitis, E. Stavropoulou, and M. Papaconstantis, “Onset of palmoplantar pustular psoriasis while on adalimumab for psoriatic arthritis: a “class effect” of TNF-α antagonists or simply an anti-psoriatic treatment adverse reaction?” Journal of Dermatological Treatment, vol. 21, no. 1, pp. 3–5, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. A. L. Croxford, S. Karbach, F. C. Kurschus, S. Wortge, A. Nikolaev, and N. Yogev, “IL-6 regulates neutrophil microabscess formation in IL-17A-driven psoriasiform lesions,” The Journal of Investigative Dermatology, vol. 134, pp. 728–735, 2014. View at Publisher · View at Google Scholar
  24. U. Huffmeier, M. Watzold, J. Mohr, M. P. Schon, and R. Mossner, “Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations,” The British Journal of Dermatology, vol. 170, no. 1, pp. 202–204, 2014. View at Publisher · View at Google Scholar
  25. F. Capon, “IL36RN mutations in generalized pustular psoriasis: just the tip of the iceberg?” Journal of Investigative Dermatology, vol. 133, no. 11, pp. 2503–2504, 2013. View at Publisher · View at Google Scholar
  26. K. Hirahara, K. Ghoreschi, A. Laurence, X. Yang, Y. Kanno, and J. J. O'Shea, “Signal transduction pathways and transcriptional regulation in Th17 cell differentiation,” Cytokine and Growth Factor Reviews, vol. 21, no. 6, pp. 425–434, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. E. Lee, W. L. Trepicchio, J. L. Oestreicher et al., “Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris,” Journal of Experimental Medicine, vol. 199, no. 1, pp. 125–130, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Aggarwal, N. Ghilardi, M. Xie, F. J. De Sauvage, and A. L. Gurney, “Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17,” Journal of Biological Chemistry, vol. 278, no. 3, pp. 1910–1914, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. L. A. Zenewicz and R. A. Flavell, “Recent advances in IL-22 biology,” International Immunology, vol. 23, no. 3, pp. 159–163, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. H. L. Rizzo, S. Kagami, K. G. Phillips, S. E. Kurtz, S. L. Jacques, and A. Blauvelt, “IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A,” Journal of Immunology, vol. 186, no. 3, pp. 1495–1502, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Sarra, R. Caruso, M. L. Cupi et al., “IL-21 promotes skin recruitment of CD4+ cells and drives IFN-γ-dependent epidermal hyperplasia,” Journal of Immunology, vol. 186, no. 9, pp. 5435–5442, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Camporeale and V. Poli, “IL-6, IL-17 and STAT3: a holy trinity in auto-immunity?” Frontiers in Bioscience, vol. 17, no. 6, pp. 2306–2326, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. P. di Meglio, F. Villanova, L. Napolitano et al., “The IL23R A/Gln381 allele promotes IL-23 unresponsiveness in human memory T-helper 17 cells and impairs Th17 responses in psoriasis patients,” Journal of Investigative Dermatology, vol. 1, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. K. E. Nograles, L. C. Zaba, E. Guttman-Yassky et al., “Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways,” British Journal of Dermatology, vol. 159, no. 5, pp. 1092–1102, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Chiricozzi, E. Guttman-Yassky, M. Suárez-Farĩas et al., “Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis,” Journal of Investigative Dermatology, vol. 131, no. 3, pp. 677–687, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. M. A. Lowes, C. B. Russell, D. A. Martin, J. E. Towne, and J. G. Krueger, “The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses,” Trends in Immunology, vol. 34, no. 4, pp. 174–181, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Chiricozzi and J. G. Krueger, “IL-17 targeted therapies for psoriasis,” Expert Opinion on Investigational Drugs, vol. 22, no. 8, pp. 993–1005, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. W. Alexander, “American academy of dermatology cardiovascular research technologies 2013 American college of cardiology,” P & T, vol. 38, no. 5, pp. 288–292, 2013. View at Google Scholar · View at Scopus
  39. O. Arican, M. Aral, S. Sasmaz, and P. Ciragil, “Serum levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity,” Mediators of Inflammation, vol. 2005, no. 5, pp. 273–279, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. A. B. Van Belle, M. De Heusch, M. M. Lemaire et al., “IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice,” Journal of Immunology, vol. 188, no. 1, pp. 462–469, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. K. El Malki, S. H. Karbach, J. Huppert et al., “An alternative pathway of imiquimod-induced psoriasis-like skin inflammation in the absence of interleukin-17 receptor a signaling,” Journal of Investigative Dermatology, vol. 133, no. 2, pp. 441–451, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. T. Mabuchi, T. Takekoshi, and S. T. Hwang, “Epidermal CCR6+γδ T cells are major producers of IL-22 and IL-17 in a murine model of psoriasiform dermatitis,” Journal of Immunology, vol. 187, no. 10, pp. 5026–5031, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. L. van der Fits, S. Mourits, J. S. A. Voerman et al., “Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis,” The Journal of Immunology, vol. 182, no. 9, pp. 5836–5845, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. R. Bissonnette, S. Nigen, R. G. Langley et al., “Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial,” Journal of the European Academy of Dermatology and Venereology, 2013. View at Publisher · View at Google Scholar
  45. S. Gregoriou, C. Kazakos, E. Christofidou, G. Kontochristopoulos, G. Vakis, and D. Rigopoulos, “Pustular psoriasis development after initial ustekinumab administration,” European Journal of Dermatology, vol. 21, no. 1, pp. 104–105, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. K. S. Wenk, J. M. Claros, and A. Ehrlich, “Flare of pustular psoriasis after initiating ustekinumab therapy,” Journal of Dermatological Treatment, vol. 23, no. 3, pp. 212–214, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Puel, S. Cypowyj, L. Maródi, L. Abel, C. Picard, and J. Casanova, “Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis,” Current Opinion in Allergy and Clinical Immunology, vol. 12, no. 6, pp. 616–622, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. H. Zhang, H. Li, Y. Li, Y. Zou, X. Dong, and W. Song, “IL-17 plays a central role in initiating experimental Candida albicans infection in mouse corneas,” European Journal of Immunology, vol. 43, no. 10, pp. 2671–2682, 2013. View at Google Scholar
  49. S. Cypowyj, C. Picard, L. Maródi, J. Casanova, and A. Puel, “Immunity to infection in IL-17-deficient mice and humans,” European Journal of Immunology, vol. 42, no. 9, pp. 2246–2254, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Gladiator, N. Wangler, K. Trautwein-Weidner, and S. LeibundGut-Landmann, “Cutting edge: IL-17-secreting innate lymphoid cells are essential for host defense against fungal infection,” The Journal of Immunology, vol. 190, no. 2, pp. 521–525, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. N. Hernández-Santos and S. L. Gaffen, “Th17 cells in immunity to Candida albicans,” Cell Host and Microbe, vol. 11, no. 5, pp. 425–435, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. A. M. Lin, C. J. Rubin, R. Khandpur et al., “Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis,” Journal of Immunology, vol. 187, no. 1, pp. 490–500, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Li, J. Han, Z. Lu et al., “Prevalent and rare mutations in IL-36RN gene in chinese patients with generalized pustular psoriasis and psoriasis vulgaris,” Journal of Investigative Dermatology, vol. 133, no. 11, pp. 2637–2639, 2013. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Marrakchi, P. Guigue, B. R. Renshaw et al., “Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis,” The New England Journal of Medicine, vol. 365, no. 7, pp. 620–628, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. J. Towne and J. Sims, “IL-36 in psoriasis,” Current Opinion in Pharmacology, vol. 12, no. 4, pp. 486–490, 2012. View at Publisher · View at Google Scholar · View at Scopus
  56. D. Tripodi, F. Conti, M. Rosati et al., “IL-36 a new member of the IL-1 family cytokines,” Journal of Biological Regulators and Homeostatic Agents, vol. 26, no. 1, pp. 7–14, 2012. View at Google Scholar · View at Scopus
  57. A. Körber, R. Mössner, R. Renner et al., “Mutations in IL36RN in patients with generalized pustular psoriasis,” Journal of Investigative Dermatology, vol. 133, no. 11, pp. 2634–2637, 2013. View at Publisher · View at Google Scholar · View at Scopus
  58. P. Muhr, J. Zeitvogel, I. Heitland, T. Werfel, and M. Wittmann, “Expression of interleukin (IL)-1 family members upon stimulation with IL-17 differs in keratinocytes derived from patients with psoriasis and healthy donors,” The British Journal of Dermatology, vol. 165, no. 1, pp. 189–193, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. H. Blumberg, H. Dinh, C. Dean Jr. et al., “IL-1RL2 and its ligands contribute to the cytokine network in psoriasis,” The Journal of Immunology, vol. 185, no. 7, pp. 4354–4362, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. Y. Carrier, H.-L. Ma, H. E. Ramon et al., “Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis,” Journal of Investigative Dermatology, vol. 131, no. 12, pp. 2428–2437, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. L. Tortola, E. Rosenwald, B. Abel et al., “Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk,” Journal of Clinical Investigation, vol. 122, no. 11, pp. 3965–3976, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. M. Uribe-Herranz, L. Lian, K. M. Hooper, K. A. Milora, and L. E. Jensen, “IL-1R1 signaling facilitates munro's microabscess formation in psoriasiform imiquimod-induced skin inflammation,” Journal of Investigative Dermatology, vol. 133, no. 6, pp. 1541–1549, 2013. View at Publisher · View at Google Scholar · View at Scopus
  63. A. Johnston, X. Xing, A. M. Guzman et al., “IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression,” Journal of Immunology, vol. 186, no. 4, pp. 2613–2622, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. L. Rossi-Semerano, M. Piram, C. Chiaverini, D. De Ricaud, A. Smahi, and I. Kone-Paut, “First clinical description of an infant with interleukin-36-receptor antagonist deficiency successfully treated with anakinra,” Pediatrics, vol. 132, no. 4, pp. e1043–e1047, 2013. View at Publisher · View at Google Scholar
  65. N. Setta-Kaffetzi, A. A. Navarini, V. M. Patel et al., “Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes,” Journal of Investigative Dermatology, vol. 133, no. 5, pp. 1366–1369, 2013. View at Publisher · View at Google Scholar · View at Scopus
  66. K. Sugiura, A. Takemoto, M. Yamaguchi et al., “The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist,” Journal of Investigative Dermatology, vol. 133, no. 11, pp. 2514–2521, 2013. View at Publisher · View at Google Scholar · View at Scopus
  67. D. M. Berki, S. K. Mahil, A. David Burden et al., “Loss of IL36RN function does not confer susceptibility to psoriasis vulgaris,” Journal of Investigative Dermatology, vol. 134, pp. 271–273, 2014. View at Publisher · View at Google Scholar · View at Scopus
  68. M. F. Neurath and S. Finotto, “IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer,” Cytokine and Growth Factor Reviews, vol. 22, no. 2, pp. 83–89, 2011. View at Publisher · View at Google Scholar · View at Scopus
  69. M. Rincon, “Interleukin-6: from an inflammatory marker to a target for inflammatory diseases,” Trends in Immunology, vol. 33, no. 11, pp. 571–577, 2012. View at Publisher · View at Google Scholar · View at Scopus
  70. S. A. Jones, J. Scheller, and S. Rose-John, “Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling,” Journal of Clinical Investigation, vol. 121, no. 9, pp. 3375–3383, 2011. View at Publisher · View at Google Scholar · View at Scopus
  71. K. Miyoshi, M. Takaishi, K. Nakajima et al., “Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA-21, a Stat3 Inhibitor,” Journal of Investigative Dermatology, vol. 131, no. 1, pp. 108–117, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. P. Ataie-Kachoie, M. H. Pourgholami, and D. L. Morris, “Inhibition of the IL-6 signaling pathway: a strategy to combat chronic inflammatory diseases and cancer,” Cytokine and Growth Factor Reviews, vol. 24, no. 2, pp. 163–173, 2013. View at Publisher · View at Google Scholar · View at Scopus
  73. S. Rose-John, “Il-6 trans-signaling via the soluble IL-6 receptor: importance for the proinflammatory activities of IL-6,” International Journal of Biological Sciences, vol. 8, no. 9, pp. 1237–1247, 2012. View at Publisher · View at Google Scholar · View at Scopus
  74. W. A. Goodman, A. D. Levine, J. V. Massari, H. Sugiyama, T. S. McCormick, and K. D. Cooper, “IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells,” Journal of Immunology, vol. 183, no. 5, pp. 3170–3176, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. K. Ishihara and T. Hirano, “IL-6 in autoimmune disease and chronic inflammatory proliferative disease,” Cytokine and Growth Factor Reviews, vol. 13, no. 4-5, pp. 357–368, 2002. View at Publisher · View at Google Scholar · View at Scopus
  76. H. Ogura, M. Murakami, Y. Okuyama et al., “Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction,” Immunity, vol. 29, no. 4, pp. 628–636, 2008. View at Publisher · View at Google Scholar · View at Scopus
  77. M. Romano, M. Sironi, C. Toniatti et al., “Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment,” Immunity, vol. 6, no. 3, pp. 315–325, 1997. View at Publisher · View at Google Scholar · View at Scopus
  78. R. M. McLoughlin, J. Witowski, R. L. Robson et al., “Interplay between IFN-γ and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation,” Journal of Clinical Investigation, vol. 112, no. 4, pp. 598–607, 2003. View at Publisher · View at Google Scholar · View at Scopus
  79. E. Bartoccioni, F. Scuderi, M. Marino, and C. Provenzano, “IL-6, monocyte infiltration and parenchymal cells,” Trends in immunology, vol. 24, no. 6, pp. 299–301, 2003. View at Google Scholar · View at Scopus
  80. G. Kaplanski, V. Marin, F. Montero-Julian, A. Mantovani, and C. Farnarier, “IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation,” Trends in Immunology, vol. 24, no. 1, pp. 25–29, 2003. View at Publisher · View at Google Scholar · View at Scopus
  81. M. Murakami and N. Nishimoto, “The value of blocking IL-6 outside of rheumatoid arthritis: current perspective,” Current Opinion in Rheumatology, vol. 23, no. 3, pp. 273–277, 2011. View at Publisher · View at Google Scholar · View at Scopus
  82. G. Horneff, “Update on biologicals for treatment of juvenile idiopathic arthritis,” Expert Opinion on Biological Therapy, vol. 13, no. 3, pp. 361–376, 2013. View at Publisher · View at Google Scholar · View at Scopus
  83. A. Castells-Rodellas, J. V. Castell, A. Ramirez-Bosca, J. F. Nicolas, F. Valcuende-Cavero, and J. Thivolet, “Interleukin-6 in normal skin and psoriasis,” Acta Dermato-Venereologica, vol. 72, no. 3, pp. 165–168, 1992. View at Google Scholar · View at Scopus
  84. P. Neuner, A. Urbanski, F. Trautinger et al., “Increased IL-6 production by monocytes and keratinocytes in patients with psoriasis,” Journal of Investigative Dermatology, vol. 97, no. 1, pp. 27–33, 1991. View at Publisher · View at Google Scholar · View at Scopus
  85. R. M. Grossman, J. Krueger, D. Yourish et al., “Interleukin 6 is expressed in high levels of psoriatic skin and stimulates proliferation of cultured human keratinocytes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 16, pp. 6367–6371, 1989. View at Publisher · View at Google Scholar · View at Scopus
  86. W. Baran, J. C. Szepietowski, G. Mazur, and E. Baran, “IL-6 and IL-10 promoter gene polymorphisms in psoriasis vulgaris,” Acta Dermato-Venereologica, vol. 88, no. 2, pp. 113–116, 2008. View at Publisher · View at Google Scholar · View at Scopus
  87. A. N. Boca, M. Talamonti, M. Galluzzo et al., “Genetic variations in IL6 and IL12B decreasing the risk for psoriasis,” Immunology Letters, vol. 156, no. 1-2, pp. 127–131, 2013. View at Publisher · View at Google Scholar
  88. T. Tejasvi, P. E. Stuart, V. Chandran et al., “TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis,” Journal of Investigative Dermatology, vol. 132, no. 3, part 1, pp. 593–600, 2012. View at Publisher · View at Google Scholar · View at Scopus
  89. L. Di Renzo, A. Bianchi, R. Saraceno et al., “174G/C IL-6 gene promoter polymorphism predicts therapeutic response to TNF-α blockers,” Pharmacogenetics and Genomics, vol. 22, no. 2, pp. 134–142, 2012. View at Publisher · View at Google Scholar · View at Scopus
  90. B. Toruniowa, D. Krasowska, M. Koziol, A. Ksiazek, and A. Pietrzak, “Serum levels of IL-6 in mycosis fungoides, psoriasis, and lichen planus,” Annals of the New York Academy of Sciences, vol. 762, pp. 432–434, 1995. View at Google Scholar · View at Scopus
  91. H. Mizutani, Y. Ohmoto, T. Mizutani, M. Murata, and M. Shimizu, “Role of increased production of monocytes TNF-α, IL-1β and IL-6 in psoriasis: Relation to focal infection, disease activity and responses to treatments,” Journal of Dermatological Science, vol. 14, no. 2, pp. 145–153, 1997. View at Publisher · View at Google Scholar · View at Scopus
  92. Y. Lo, K. Torii, C. Saito, T. Furuhashi, A. Maeda, and A. Morita, “Serum IL-22 correlates with psoriatic severity and serum IL-6 correlates with susceptibility to phototherapy,” Journal of Dermatological Science, vol. 58, no. 3, pp. 225–227, 2010. View at Publisher · View at Google Scholar · View at Scopus
  93. M.-M. Suttle, G. Nilsson, E. Snellman, and I. T. Harvima, “Experimentally induced psoriatic lesion associates with interleukin (IL)-6 in mast cells and appearance of dermal cells expressing IL-33 and IL-6 receptor,” Clinical and Experimental Immunology, vol. 169, no. 3, pp. 311–319, 2012. View at Publisher · View at Google Scholar · View at Scopus
  94. S. Fujishima, H. Watanabe, M. Kawaguchi et al., “Involvement of IL-17F via the induction of IL-6 in psoriasis,” Archives of Dermatological Research, vol. 302, no. 7, pp. 499–505, 2010. View at Publisher · View at Google Scholar · View at Scopus
  95. A. Hänsel, C. Günther, J. Ingwersen et al., “Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong Th17/Th1 T-cell responses,” Journal of Allergy and Clinical Immunology, vol. 127, no. 3, pp. 787–794, 2011. View at Publisher · View at Google Scholar · View at Scopus
  96. J. Lindroos, L. Svensson, H. Norsgaard et al., “IL-23-mediated epidermal hyperplasia is dependent on IL-6,” Journal of Investigative Dermatology, vol. 131, no. 5, pp. 1110–1118, 2011. View at Publisher · View at Google Scholar · View at Scopus
  97. K. Nakajima, T. Kanda, M. Takaishi et al., “Distinct roles of IL-23 and IL-17 in the development of psoriasis-like lesions in a mouse model,” The Journal of Immunology, vol. 186, no. 7, pp. 4481–4489, 2011. View at Publisher · View at Google Scholar · View at Scopus
  98. S. Sano, K. S. Chan, S. Carbajal et al., “Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model,” Nature Medicine, vol. 11, no. 1, pp. 43–49, 2005. View at Publisher · View at Google Scholar · View at Scopus
  99. R. M. Andrés, M. C. Montesinos, P. Navalón, M. Payá, and M. C. Terencio, “NF-κB and STAT3 Inhibition as a therapeutic strategy in psoriasis: in vitro and in vivo effects of BTH,” Journal of Investigative Dermatology, vol. 133, no. 10, pp. 2362–2371, 2013. View at Publisher · View at Google Scholar · View at Scopus
  100. J. Kamarashev, P. Lor, A. Forster, L. Heinzerling, G. Burg, and F. O. Nestle, “Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept,” Dermatology, vol. 205, no. 2, pp. 213–216, 2002. View at Publisher · View at Google Scholar · View at Scopus
  101. M. Yamamoto, Y. Imai, Y. Sakaguchi, T. Haneda, and K. Yamanishi, “Serum cytokines correlated with the disease severity of generalized pustular psoriasis,” Disease Markers, vol. 34, no. 3, pp. 153–161, 2013. View at Publisher · View at Google Scholar · View at Scopus
  102. T. Nakamura, M. Oishi, M. Johno, T. Ono, and M. Honda, “Serum levels of interleukin 6 in patients with pustulosis palmaris et plantaris,” Journal of Dermatology, vol. 20, no. 12, pp. 763–766, 1993. View at Google Scholar · View at Scopus
  103. H. Murakata, Y. Harabuchi, Y. Kukuminato, Y. Yokoyama, and A. Kataura, “Cytokine production by tonsillar lymphocytes stimulated with alpha-streptococci in patients with pustulosis palmaris et plantaris,” Acta Oto-Laryngologica, Supplement, vol. 523, pp. 201–203, 1996. View at Google Scholar · View at Scopus
  104. K. A. Papp, C. Leonardi, A. Menter et al., “Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis,” The New England Journal of Medicine, vol. 366, no. 13, pp. 1181–1189, 2012. View at Publisher · View at Google Scholar · View at Scopus
  105. A. Grasland, E. Mahé, E. Raynaud, and I. Mahé, “Psoriasis onset with tocilizumab,” Joint Bone Spine, vol. 80, no. 5, pp. 541–542, 2013. View at Publisher · View at Google Scholar · View at Scopus
  106. D. Wendling, H. Letho-Gyselinck, X. Guillot, and C. Prati, “Psoriasis onset with tocilizumab treatment for rheumatoid arthritis,” Journal of Rheumatology, vol. 39, no. 3, p. 657, 2012. View at Publisher · View at Google Scholar · View at Scopus
  107. K. A. Papp, A. Menter, B. Strober et al., “Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study,” British Journal of Dermatology, vol. 167, no. 3, pp. 668–677, 2012. View at Publisher · View at Google Scholar · View at Scopus
  108. K. Ghoreschi and M. Gadina, “Jakpot! new small molecules in autoimmune and inflammatory diseases,” Experimental Dermatology, vol. 23, no. 1, pp. 7–11, 2013. View at Publisher · View at Google Scholar
  109. S. Younis, D. Rimar, G. Slobodin, and I. Rosner, “Tumor necrosis factor-associated palmoplantar pustular psoriasis treated with interleukin 6 blocker,” Journal of Rheumatology, vol. 39, no. 10, pp. 2055–2056, 2012. View at Publisher · View at Google Scholar · View at Scopus
  110. J. Rueda-Gotor, M. A. González-Gay, R. Blanco Alonso, C. Gonzalez-Vela, C. Lopez-Obregon, and M. A. González-López, “Successful effect of tocilizumab in anti-TNF-α-induced palmoplantar pustulosis in rheumatoid arthritis,” Joint Bone Spine, vol. 79, no. 5, pp. 510–513, 2012. View at Publisher · View at Google Scholar · View at Scopus